Emergent BioSolutions has secured a $628m contract from the US Biomedical Advanced Research and Development Authority (BARDA) for domestic manufacturing of Covid-19 vaccine candidates.
The company will provide its contract development and manufacturing (CDMO) capacities, capabilities and expertise as part of the government’s Warp Speed Program to speed-up access to vaccines against Covid-19.
This task order falls under Emergent’s 2012 contract with BARDA, which recognises the company’s Baltimore Bayview facility as a Center for Innovation in Advanced Development and Manufacturing (CIADM) for pandemic preparedness.